ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Citing growing demand for small-molecule drug services, Cambrex says it will spend over $30 million to expand its plant in High Point, North Carolina. The company plans to add two clinical-scale manufacturing suites and a commercial-scale operation with 2,000 L reactors. It will also establish a 500 kg per year facility for orphan drugs and niche therapies. The projects will add 78 jobs at the site. Cambrex got the High Point plant in its acquisition of PharmaCore in 2016.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X